CARLSBAD, Calif., April 5 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR), a biopharmaceutical company developing immune-
based therapies (IBT) for HIV and select other diseases, announced today that
in its 2003 financial statements included in the Company's Form 10-K filed
last week, the audit opinion of BDO Seidman, LLP contained a going-concern
qualification.
Nasdaq's rules require Nasdaq-listed companies to publicly announce
whenever a Form 10-K includes an audit opinion containing a going-concern
qualification.
About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is developing immune-based
therapies (IBT) for HIV and select other diseases. The Company's HIV products
are based on its patented whole-killed virus technology, co-invented by
Company founder, Dr. Jonas Salk, to stimulate broad and potent HIV immune
responses. REMUNE(R), currently in Phase II, is being developed as a first
line treatment for people with early-stage HIV. The Company has initiated
development of a new IBT, IR103, which incorporates a state-of-the-art immune
system booster.
The Immune Response Corporation is also developing an IBT for Multiple
Sclerosis (MS), NeuroVax(TM), which is currently in Phase II and has shown
potential therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation on the World Wide Web at
http://www.imnr.com
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including whether the Company will continue as a going concern and
successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of NeuroVax (TM), the uncertainty of
successful completion of any such clinical trials, whether NeuroVax(TM), will
be effective as either a preventive or therapeutic vaccine, whether future
trials will be conducted and whether the results of such trials will coincide
with the results of NeuroVax(TM), in preclinical trials. These risks, among
others, are set forth in The Immune Response Corporation's SEC filings
including, but not limited to, its Annual Report on Form 10-K for the year
ended December 31, 2003. The Company undertakes no obligation to update the
results of these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
NeuroVax(TM) is a trademark of The Immune Response Corporation. REMUNE(R) is
a registered trademark of The Immune Response Corporation.
MEDIA CONTACT:
Laura Silver, Sam Brown Inc. Corporate Communications
310-551-9940
silver@sambrown.com
INVESTOR RELATIONS CONTACT:
Kathy Waller, Financial Relations Board
312-266-7800
kwaller@financialrelationsboard.com
AT THE COMPANY:
Michael K. Green, Chief Financial Officer
760-431-7080
info@imnr.com
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
media, Laura Silver of Sam Brown Inc.
Corporate Communications, +1-310-551-9940, silver@sambrown.com,
or investor relations, Kathy Waller of Financial Relations Board,
+1-312-266-7800, kwaller@financialrelationsboard.com, both for
The Immune Response Corporation; or Michael K. Green, Chief
Financial Officer of The Immune Response Corporation,
+1-760-431-7080, info@imnr.com
|
